Generic and low dose antiretroviral therapy in adults and children: Implication for scaling up treatment in resource limited settings

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Ramautarsing, Reshmie ^a,b   Ananworanich, Jintanat ^a,c,d  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Southeast Asia Research Collaboration with Hawaii (SEARCH)   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GENERIC DRUG; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIFAMPICIN; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANEMIA; ASIAN; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ETHNICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LOW DRUG DOSE; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PSYCHOPATHY; RESOURCE ALLOCATION; REVIEW; SCALE UP; UNSPECIFIED SIDE EFFECT;

EID: 77953719289     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-18     Document Type: Review

References (60)

1. UNAIDS Factsheet 2009. Global Facts & Figures. 2009, UNAIDS.
2. WHO Antiretroviral therapy data and statistics. 2009, WHO.
3. WHO Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. 2009, WHO.
4. FDA FDA Antiretrovirals Approved and Tentatively Approved in Association with the President's Emergency Plan Expedited Review Process. FDA.
5. Narang VS, Lulla A, Malhotra G, Purandare S. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects. J Clin Pharmacol 2005, 45:265-274. 10.1177/0091270004273343, 15703362.
6. van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D, Gorowara M, Phanuphak P, Ruxrungtham K. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. Antivir Ther 2009, 14:1001-1004. 10.3851/IMP1410, 19918104.
7. Ramautarsing R, Gorowara M, van der Lugt J, Wongsabut J, Khongpetch C, Phanuphak P, Burger D, Ruxrungtham K. A. Generic lopinavir/ritonavir is bioequivalent to Aluvia, but neither result in adequate lopinavir exposure at 50% dose reduction: HIVNAT 085. 11th International Workshop on Clinical Pharmacology of HIV Therapy Sorrento, Italy 2010,
8. Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection. J Med Assoc Thai 2006, 89:1472-1478.
9. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263. 10.1016/S0140-6736(04)15997-7, 15094269.
10. Kiertiburanakul S, Khongnorasat S, Rattanasiri S, Sungkanuparph S. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai 2007, 90:237-243.
11. Pujari S, Dravid A, Gupte N, Joshix K, Bele V. Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India. J Int AIDS Soc 2008, 10:196. 10.1186/1758-2652-10-8-196, 2757396, 19825144.
12. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama 2004, 292:191-201. 10.1001/jama.292.2.191, 15249568.
13. Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010, 50:787-791. 10.1086/650539, 20121419.
14. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007, 8:164-172. 10.1310/hct0803-164, 17621463.
15. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, Balakrishnan P, Yepthomi T, Poongulali S, Flanigan TP, Solomon S, Mayer KH. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 2008, 22:337-344. 10.1089/apc.2007.0093, 18422462.
16. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006, 7:156-162. 10.1111/j.1468-1293.2006.00355.x, 16494629.
17. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010, 170:57-65. 10.1001/archinternmed.2009.432, 20065200.
18. Sivadasan A, Abraham OC, Rupali P, Pulimood SA, Rajan J, Rajkumar S, Zachariah A, Kannangai R, Kandathip AJ, Sridharan G, Mathai D. High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. J Assoc Physicians India 2009, 57:384-388.
19. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. 2009,
20. EACS EACS Guidelines verdion 5. Clinical management and treatment of HIV infected adults in Europe. 2009, EACS.
21. WHO Rapid advice. Antiretroviral therapy for HIV infection in adults and adolescents. 2009, WHO.
22. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, Milinkovic A, Gatell J, Ribera E. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007, 8:679-688. 10.1517/14656566.8.5.679, 17376022.
23. Dionisio D, Gass R, McDermott P, Racalbuto V, Madeo M, Braghieri G, Crowley S, Pinheiro Edos S, Graaff P, Vasan A, Eksaengsri A, Moller H, Khanna AK, Kraisintu K, Juneja S, Nicolaou S, Sengupta A, Esperti F, Messeri D. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?. Curr HIV Res 2007, 5:155-187. 10.2174/157016207780077075, 17346132.
24. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, Sirisanthana V. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J 2007, 26:953-956. 10.1097/INF.0b013e318125720a, 17901804.
25. Prasitsuebsai W, Bowen AC, Pang J, Hesp C, Kariminia A, Sohn AH. Pediatric HIV clinical care resources and management practices in Asia: a regional survey of the TREAT Asia pediatric network. AIDS Patient Care STDS 2010, 24:127-131. 10.1089/apc.2009.0224, 20059355.
26. Zhang F, Haberer J, Wei H, Wang N, Chu A, Zhao Y, Zhao H. Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. Int J STD AIDS 2009, 20:406-409. 10.1258/ijsa.2008.008357, 19451326.
27. Sohn A, J A. HAART for children with treatment failure. HIV Ther 2009, 3:485-499.
28. DHHS Guidelines for the Use of Antiretroviral Agents in Pediatric HIV infection. 2009, DHHS.
29. Puthanakit T, Chokephaibulkit K, Suntarattiwong P, Gorowara M, Leawsrisuk P, Suwanlerk T, Boonrak P, Ruxrungtham K. Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets. Pediatr Infect Dis J 2010, 29:79-82. 10.1097/INF.0b013e3181b21040, 19858772.
30. Gonzalez de Requena D, Blanco F, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS 2003, 17:443-445. 10.1089/108729103322395465, 14588081.
31. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther 2009, 14:241-248.
32. Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2007, 26:86-88. 10.1097/01.inf.0000247140.94669.1b, 17195716.
33. Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, van Leeuwen R, Weverling GJ, Kunanusont C, Lange JM, Cooper DA, Phanuphak P. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. Aids 2000, 14:1375-1382. 10.1097/00002030-200007070-00010, 10930152.
34. Wattanagoon Y, Na Bangchang K, Hoggard PG, Khoo SH, Gibbons SE, Phiboonbhanakit D, Karbwang J, Back DJ. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers. Antimicrob Agents Chemother 2000, 44:1986-1989. 10.1128/AAC.44.7.1986-1989.2000, 89999, 10858368.
35. Cressey TR, Leenasirimakul P, Jourdain G, Tawon Y, Sukrakanchana PO, Lallemant M. Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 42:387-389. 10.1097/01.qai.0000221685.90681.1b, 16810125.
36. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, Sarasanacenta M, Lopez-Pua Y, Pachon J. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002, 41:681-690. 10.2165/00003088-200241090-00004, 12126459.
37. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, Ruxrungtham K. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. Aids 2005, 19:1481-1486. 10.1097/01.aids.0000183630.27665.30, 16135901.
38. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. Aids 2006, 20:131-132. 10.1097/01.aids.0000196181.18916.9b, 16327334.
39. Avihingsanon A, van der Lugt J, Gorowara M, Boonrak P, Jina S, Phanuphak P, Burger D, R R. A low dose of efavirenz provides adequate efavirenz plasma concentrations in Thai HIV-1 infected adults. AIDS 2008 - XVII International AIDS Conference. Mexico City 2008,
40. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G > T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005, 40:1358-1361. 10.1086/429327, 15825040.
41. Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V. Plasma efavirenz concentrations and the association with CYP2B6-516G > T polymorphism in HIV-infected Thai children. Antivir Ther 2009, 14:315-320.
42. Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Ocana I, Ruiz I, Pahissa A. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001, 28:450-453.
43. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, Sujaikaew K, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K, Burger DM. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005, 10:937-943.
44. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, Gorowara M, Yamada N, Yanai H, Mitarai S, Ishikawa N, Cooper DA, Phanuphak P, Burger D, Ruxrungtham K. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther 2008, 13:529-536.
45. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005, 10:301-307.
46. Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004, 54:785-790. 10.1093/jac/dkh415, 15329366.
47. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008, 13:375-380.
48. Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther 2005, 10:761-767.
49. van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K, Burger D. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 2008, 61:1145-1153. 10.1093/jac/dkn050, 18285316.
50. Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008, 27:623-628. 10.1097/INF.0b013e31816b4539, 18520443.
51. Avihingsanon A, van der Lugt J, Kerr SJ, Gorowara M, Chanmano S, Ohata P, Lange J, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther 2009, 85:402-408. 10.1038/clpt.2008.244, 19118378.
52. Chetchotisakd P, Anunnatsiri S. Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand. J Acquir Immune Defic Syndr 2008, 49:230-231. 10.1097/QAI.0b013e31817cfdc9, 18820535.
53. Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother 2009, 64:1080-1086. 10.1093/jac/dkp322, 19729375.
54. Hill A, van der Lugt J, Sawyer W, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. Aids 2009, 23:2237-2245. 10.1097/QAD.0b013e328332c3a5, 19809270.
55. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005, 44:989-1008. 10.2165/00003088-200544100-00001, 16176115.
56. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol 2001, 25:120-123. 10.1053/sper.2001.24565, 11453606.
57. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. Reduced lopinavir exposure during pregnancy. Aids 2006, 20:1931-1939. 10.1097/01.aids.0000247114.43714.90, 16988514.
58. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008, 49:485-491. 10.1097/QAI.0b013e318186edd0, 18989231.
59. Perinatal HIV Guidelines Working Group. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and to reduce perinatal HIV transmission in the United States. 2009,
60. Ramautarsing R, van der Lugt L, Phanuphak N, Gorowara M, Kerr S, Chuemchaitrakool A, Phanuphak P, Ruxrungtham K, Burger D, S C. Standard dose generic lopinavir/ritonavir provides adequate lopinavir plasma levels during the 3rd trimester of pregnancy in Thai HIV-1 infected women. 11th International Workshop on Clinical Pharmacology of HIV Therapy. Sorrento, Italy 2010,